Association of vasoactive intestinal peptide with polymer-grafted liposomes: Structural aspects for pulmonary delivery

被引:41
作者
Stark, Brigitte
Debbage, Paul
Andreae, Fritz
Mosgoeller, Wilhelm
Prassl, Ruth
机构
[1] Austrian Acad Sci, Inst Biophys & Nanosyst Res, A-8042 Graz, Austria
[2] Med Univ Innsbruck, Dept Anat Histol & Embryol, Innsbruck, Austria
[3] piCHEM Res & Dev, Graz, Austria
[4] Med Univ Vienna, Inst Canc Res, Vienna, Austria
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 2007年 / 1768卷 / 03期
基金
奥地利科学基金会;
关键词
polyethlene glycolated liposome; sterically stabilized liposome; nanostructure; amphipathic peptide; peptide-lipid interaction;
D O I
10.1016/j.bbamem.2006.11.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A polymer-grafted liposomal formulation that has the potential to be developed for aerosolic pulmonary delivery of vasoactive intestinal peptide (VIP), a potent vasodilatory neuropeptide, is described. As VIP is prone to rapid proteolytic degradation in the microenvironment of the lung a proper delivery system is required to increase the half-life and bioavailability of the peptide. Here we investigate structural parameters of unilamellar liposomes composed of palmitoyl-oleoyl-pho sphatidylcho line, lyso-stearyl-phosphatidylglycerol and distearyl-phosphatidylethanolamine covalently linked to polyethylene glycol 2000, and report on VIP-lipid interaction mechanisms. We found that the cationic VIP is efficiently entrapped by the negatively charged spherical liposomes and becomes converted to an amphipathic CL-helix. By fluorescence spectroscopy using single Trp-modified VIP we could show that VIP is closely associated to the membrane. Our data suggest that the N-terminal random-coiled domain is embedded in the interfacial headgroup region of the phospholipid bilayer. By doing so, neither the bilayer thickness of the lipid membrane nor the mobility of the phospholipid acyl chains are affected as shown by small angle X-ray scattering and electron spin resonance spectroscopy. Finally, in an ex vivo lung arterial model system we found that liposomal-associated VIP is recognized by its receptors to induce vasodilatory effects with comparable high relaxation efficiency as free VIP but with a significantly retarded dilatation kinetics. In conclusion, we have designed and characterized a liposomal formulation that is qualified to entrap biologically active VIP and displays structural features to be considered for delivery of VIP to the lung. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:705 / 714
页数:10
相关论文
共 50 条
[21]   Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors [J].
Groneberg, DA ;
Rabe, KF ;
Fischer, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 533 (1-3) :182-194
[22]   ENZYMATIC DEGRADATION OF HELODERMIN AND VASOACTIVE INTESTINAL POLYPEPTIDE [J].
HACHISU, M ;
HIRANUMA, T ;
TANI, S ;
IIZUKA, T .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1991, 14 (03) :126-131
[23]   Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation - Analysis in neuronal nitric oxide synthase knockout mice [J].
Hasaneen, NA ;
Foda, HD ;
Said, SI .
CHEST, 2003, 124 (03) :1067-1072
[24]   VIP RECEPTORS IN MESENTERIC AND CORONARY-ARTERIES - A RADIOLIGAND BINDING STUDY [J].
HUANG, M ;
RORSTAD, OP .
PEPTIDES, 1987, 8 (03) :477-485
[25]   Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch [J].
Ikezaki, H ;
Paul, S ;
Alkan-Onyuksel, H ;
Patel, M ;
Gao, XP ;
Rubinstein, I .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1998, 275 (01) :R56-R62
[26]   Protein secondary structure prediction based on position-specific scoring matrices [J].
Jones, DT .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 292 (02) :195-202
[27]  
Keith IM, 2000, PHYSIOL RES, V49, P519
[28]   RANGE AND MAGNITUDE OF THE STERIC PRESSURE BETWEEN BILAYERS CONTAINING PHOSPHOLIPIDS WITH COVALENTLY ATTACHED POLY(ETHYLENE GLYCOL) [J].
KENWORTHY, AK ;
HRISTOVA, K ;
NEEDHAM, D ;
MCINTOSH, TJ .
BIOPHYSICAL JOURNAL, 1995, 68 (05) :1921-1936
[29]   Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications [J].
Labiris, NR ;
Dolovich, MB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :600-612
[30]   Novel applications of liposomes [J].
Lasic, DD .
TRENDS IN BIOTECHNOLOGY, 1998, 16 (07) :307-321